NYR reduces secondary brain injury via the reduction of calcium influx in the brain cell
AGN reduces secondary and brain injury via the reduction of calcium influx in the brain cell
You are not the only drug that does what it does. NYR is a drug molecule, AGN is a peptide. NYR is more readily available as a molecule and worth significantly less to produce and the formulations it can come in are significantly greater
Both will revolutionise the secondary brain injury space but don’t think your alone. However to compare market caps of 6 million for NYR and 100 million for AGN when both work the same to reduce secondary brain injury by reducing calcium influx by inhibiting the receptors on the brain cell in charge of allowing calcium in. The bigger return of investment right now is the other
AGN Media thread, page-98
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.5¢ |
Change
-0.015(1.88%) |
Mkt cap ! $99.79M | |||
| Open | High | Low | Value | Volume |
| 80.0¢ | 83.5¢ | 78.5¢ | $114.3K | 142.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16560 | 78.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| AGN (ASX) Chart |